174 related articles for article (PubMed ID: 34380370)
1. Levoketoconazole: a novel treatment for endogenous Cushing's syndrome.
Fleseriu M; Auchus RJ; Pivonello R; Salvatori R; Zacharieva S; Biller BMK
Expert Rev Endocrinol Metab; 2021 Jul; 16(4):159-174. PubMed ID: 34380370
[No Abstract] [Full Text] [Related]
2. Levoketoconazole, the 2S,4R Enantiomer of Ketoconazole, a New Steroidogenesis Inhibitor for Cushing's Syndrome Treatment.
Creemers SG; Feelders RA; de Jong FH; Franssen GJH; de Rijke YB; van Koetsveld PM; Hofland LJ
J Clin Endocrinol Metab; 2021 Mar; 106(4):e1618-e1630. PubMed ID: 33399817
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial.
Fleseriu M; Pivonello R; Elenkova A; Salvatori R; Auchus RJ; Feelders RA; Geer EB; Greenman Y; Witek P; Cohen F; Biller BMK
Lancet Diabetes Endocrinol; 2019 Nov; 7(11):855-865. PubMed ID: 31542384
[TBL] [Abstract][Full Text] [Related]
4. Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing's syndrome.
Geer EB; Salvatori R; Elenkova A; Fleseriu M; Pivonello R; Witek P; Feelders RA; Bex M; Borresen SW; Puglisi S; Biller BMK; Cohen F; Pecori Giraldi F
Pituitary; 2021 Feb; 24(1):104-115. PubMed ID: 33216275
[TBL] [Abstract][Full Text] [Related]
5. Levoketoconazole in the Treatment of Patients With Cushing's Syndrome and Diabetes Mellitus: Results From the SONICS Phase 3 Study.
Pivonello R; Elenkova A; Fleseriu M; Feelders RA; Witek P; Greenman Y; Geer EB; Perotti P; Saiegh L; Cohen F; Arnaldi G
Front Endocrinol (Lausanne); 2021; 12():595894. PubMed ID: 33897615
[TBL] [Abstract][Full Text] [Related]
6. Levoketoconazole in the treatment of patients with endogenous Cushing's syndrome: a double-blind, placebo-controlled, randomized withdrawal study (LOGICS).
Pivonello R; Zacharieva S; Elenkova A; Tóth M; Shimon I; Stigliano A; Badiu C; Brue T; Georgescu CE; Tsagarakis S; Cohen F; Fleseriu M
Pituitary; 2022 Dec; 25(6):911-926. PubMed ID: 36085339
[TBL] [Abstract][Full Text] [Related]
7. Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies.
Fleseriu M; Castinetti F
Pituitary; 2016 Dec; 19(6):643-653. PubMed ID: 27600150
[TBL] [Abstract][Full Text] [Related]
8. Cushing's disease: adrenal steroidogenesis inhibitors.
Pivonello R; Simeoli C; Di Paola N; Colao A
Pituitary; 2022 Oct; 25(5):726-732. PubMed ID: 36036308
[TBL] [Abstract][Full Text] [Related]
9. Corticotropin-dependent Cushing's syndrome in older people: presentation of five cases and therapeutical use of ketoconazole.
Berwaerts JJ; Verhelst JA; Verhaert GC; Verhaegen AA; Abs RE
J Am Geriatr Soc; 1998 Jul; 46(7):880-4. PubMed ID: 9670876
[TBL] [Abstract][Full Text] [Related]
10. Therapy of Cushing's syndrome with steroid biosynthesis inhibitors.
Engelhardt D; Weber MM
J Steroid Biochem Mol Biol; 1994 Jun; 49(4-6):261-7. PubMed ID: 8043488
[TBL] [Abstract][Full Text] [Related]
11. Ketoconazole treatment in Cushing's disease. Effect on the circadian profile of plasma ACTH and cortisol.
Terzolo M; Panarelli M; Piovesan A; Torta M; Paccotti P; Angeli A
J Endocrinol Invest; 1988 Nov; 11(10):717-21. PubMed ID: 2852693
[TBL] [Abstract][Full Text] [Related]
12. Approach to the Patient Treated with Steroidogenesis Inhibitors.
Castinetti F; Nieman LK; Reincke M; Newell-Price J
J Clin Endocrinol Metab; 2021 Jun; 106(7):2114-2123. PubMed ID: 33675650
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy and long-term tolerance of ketoconazole in the treatment of Cushing's disease].
Tabarin A; Navarranne A; Corcuff B; Guerin J; Kern AM; Roger P
Ann Endocrinol (Paris); 1990; 51(1):27-32. PubMed ID: 2171415
[TBL] [Abstract][Full Text] [Related]
14. Prolonged treatment of Cushing's disease by ketoconazole.
Sonino N; Boscaro M; Merola G; Mantero F
J Clin Endocrinol Metab; 1985 Oct; 61(4):718-22. PubMed ID: 4031015
[TBL] [Abstract][Full Text] [Related]
15. Updates in adrenal steroidogenesis inhibitors for Cushing's syndrome - A practical guide.
Varlamov EV; Han AJ; Fleseriu M
Best Pract Res Clin Endocrinol Metab; 2021 Jan; 35(1):101490. PubMed ID: 33707082
[TBL] [Abstract][Full Text] [Related]
16. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome.
Kamenický P; Droumaguet C; Salenave S; Blanchard A; Jublanc C; Gautier JF; Brailly-Tabard S; Leboulleux S; Schlumberger M; Baudin E; Chanson P; Young J
J Clin Endocrinol Metab; 2011 Sep; 96(9):2796-804. PubMed ID: 21752886
[TBL] [Abstract][Full Text] [Related]
17. Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials.
Pivonello R; Ferrigno R; De Martino MC; Simeoli C; Di Paola N; Pivonello C; Barba L; Negri M; De Angelis C; Colao A
Front Endocrinol (Lausanne); 2020; 11():648. PubMed ID: 33363514
[TBL] [Abstract][Full Text] [Related]
18. An evaluation of pharmacological options for Cushing's disease: what are the state-of-the-art options?
Martino M; Aboud N; Lucchetti B; Salvio G; Arnaldi G
Expert Opin Pharmacother; 2023 Apr; 24(5):557-576. PubMed ID: 36927238
[TBL] [Abstract][Full Text] [Related]
19. A polymorphism in the CYP17A1 gene influences the therapeutic response to steroidogenesis inhibitors in Cushing's syndrome.
Valassi E; Aulinas A; Glad CA; Johannsson G; Ragnarsson O; Webb SM
Clin Endocrinol (Oxf); 2017 Nov; 87(5):433-439. PubMed ID: 28665508
[TBL] [Abstract][Full Text] [Related]
20. Levoketoconazole treatment in endogenous Cushing's syndrome: extended evaluation of clinical, biochemical, and radiologic outcomes.
Fleseriu M; Auchus RJ; Greenman Y; Zacharieva S; Geer EB; Salvatori R; Pivonello R; Feldt-Rasmussen U; Kennedy L; Buchfelder M; Biller BM; Cohen F; Heaney AP
Eur J Endocrinol; 2022 Dec; 187(6):859-871. PubMed ID: 36251618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
